Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma
Blood (2011)
  • Ajay K. Gopal, University of Washington
  • Ted Gooley, Fred Hutchinson Cancer Research Center
  • Joseph Rajendran, University of Washington
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Darrell R. Fisher, Pacific Northwest National Laboratory
  • David G. Maloney, Fred Hutchinson Cancer Research Center
  • Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center
  • Andrew Shields, University of Washington
  • Oliver W. Press, Fred Hutchinson Cancer Research Center
Link
Disciplines
Publication Date
November 18, 2011
Citation Information
Ajay K. Gopal, Ted Gooley, Joseph Rajendran, John M. Pagel, et al.. "A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma" Blood Vol. 118 Iss. 21 (2011) p. 663 - 663
Available at: http://works.bepress.com/john-pagel/165/